他莫昔芬(TAM)是目前治疗乳腺癌的有效药物之一。它是一种非甾类抗雌激素药物,主要在肿瘤细胞水平通过与雌激素受体结合,竞争性抑制雌二醇而产生治疗作用。近年来越来越多的实验和临床资料表明,TAM不仅仅是竞争性结合雌激素受体,而且也影响其他体内物质,如抑制蛋白激酶C、调钙蛋白,阻滞组胺受体等,因此,笔者将有关TAM治疗非乳癌肿瘤的报道作一综述。 Tamoxifen (TAM) is currently one of the effective drugs for the treatment of breast cancer. It is a non-steroidal anti-estrogen drug that exerts a therapeutic effect mainly at the tumor cell level by competitively inhibiting estradiol by binding to the estrogen receptor. In recent years, more and more experimental and clinical data show that, TAM is not only a competitive combination of estrogen receptors, but also affect other substances in the body, such as inhibition of protein kinase C, calmodulin, block histamine receptors, Therefore, I will report on TAM treatment of non-breast cancer to make a review.